|
Phase II multicentric uncontrolled national trial assessing the efficacy of nilotinib in the treatment of advanced melanomas with c-KIT mutation or amplification: Results of the pharmacodynamic study. |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Roche Pharma AG |
| |
|
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Roche Pharma AG |
Consulting or Advisory Role - GlaxoSmithKline; MSD; Roche Pharma AG |
Travel, Accommodations, Expenses - Roche Pharma AG |
| |
|
No Relationships to Disclose |
| |
|
|
Research Funding - Roche Pharma AG (Inst) |
Travel, Accommodations, Expenses - Roche Pharma AG |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Roche |
Travel, Accommodations, Expenses - Roche Pharma AG |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Roche Pharma AG |
| |
|
No Relationships to Disclose |
| |
|
Leadership - Amgen; Bristol-Myers Squibb; Roche Pharma AG |
Honoraria - Bristol-Myers Squibb; Roche Pharma AG |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Roche Pharma AG |
Expert Testimony - Amgen; Bristol-Myers Squibb; Roche Pharma AG |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche Pharma AG |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; MSD; Roche Pharma AG |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; MSD; Roche Pharma AG |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; MSD; Roche Pharma AG |
Research Funding - Roche Pharma AG |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Roche Pharma AG |
Consulting or Advisory Role - GlaxoSmithKline; Novartis; Roche Pharma AG |
| |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis |
Travel, Accommodations, Expenses - Roche |